---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-22-000039"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:56:29.533602+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q2 revenue $91.4M (+73%), net loss $14.5M; FY guidance raised to $354M-$362M

## Summary
- Q2 revenue $91.4M (+73% YoY); U.S. $87.9M (+78%), ex-U.S. $3.5M (-3% due to FX).
- GAAP net loss $14.5M ($0.53 diluted EPS) vs $13.1M ($0.48) prior year; gross margin 84.5% (down from 85.8%).
- FY2022 revenue guidance raised to $354M-$362M (from $336M-$344M); gross margin guidance lowered to 83%-85%.
- Activated 52 new U.S. centers in Q2 (total 785); added 17 U.S. sales territories (total 191).
- Received FDA approval for expanded full-body MRI; Breakthrough Device Designation for expanded AHI/BMI indication.

## SEC filing metadata
- accession: 0001609550-22-000039
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955022000039/0001609550-22-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955022000039/insp-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-22-000039
- JSON: https://secwatch.observer/filing/0001609550-22-000039.json
- Plain text: https://secwatch.observer/filing/0001609550-22-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.